

CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 20 November 2024

ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY

SCENESSE® dosage expansion under review by European Medicines Agency

CLINUVEL seeks global harmonisation of EPP label

EXECUTIVE SUMMARY

1. expert physicians & patients demand to expand EU SCENESSE® label
2. final discussions ongoing with European regulators (EMA-PRAC)
3. submission of real-world evidence, long-term use data
4. outcome expected in Q1 2025

CLINUVEL is in late-stage discussions with the European Medicines Agency (EMA) to increase the recommended maximum number of doses per year of its drug SCENESSE® (afamelanotide 16mg) for adult patients with erythropoietic protoporphyria (EPP).

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing all aspects of risk management of human medicines. The PRAC will decide over the coming months whether to maintain the existing SCENESSE® label – including frequency of prescription – or expand it to a higher dosage of up to six times per year. If approved by the EMA, the European use of SCENESSE® would be harmonised with that approved in other jurisdictions (including by the US Food and Drug Administration, FDA), enabling European EPP patients to receive year-round treatment. An outcome is expected in Q1 2025.

Label harmonisation

SCENESSE® is administered to EPP patients every two months as a bioresorbable injectable implant. The drug's European label currently includes a "recommended maximum" of four implants per annum.

Expert physicians in Europe have actively treated patients with more than four doses per annum (one dose every two months) to ensure that their patients receive year-round photoprotection. Feedback from clinics and patients – as well as in peer-reviewed literature – is that it is medically necessary for some patients to receive continuous treatment. Based on analyses of those patients receiving more than four implants, it is apparent that the safety profile of the drug has remained unchanged and favourable. As a result of clinical demand, CLINUVEL has analysed and presented clinical and real-world evidence to the EMA supporting label harmonisation.

To date, the majority of EPP patients treated globally are receiving four or more implants in a single treatment year.

Global use of SCENESSE®

SCENESSE® was approved by the European Commission in December 2014 and launched in Europe in June 2016. Administered by healthcare professionals through a network of accredited European EPP Expert Centres, SCENESSE® provides systemic photoprotection to EPP patients, reducing the incidence and severity

of incapacitating phototoxic reactions, enabling greater pain-free direct sunlight exposure, and allowing patients to lead more 'normal' lives.

Since the product's launch, CLINUVEL has deliberately maintained a strict risk management plan (RMP), controlling the distribution of SCENESSE® and monitoring the use of the therapy through the European EPP Disease Registry (EEDR). The Company estimates that more than 85% of European EPP patients treated with SCENESSE® have provided pseudonymised data through the EEDR, reporting on safety and effectiveness outcomes. Long-term data on the drug's use in EPP have been published and presented, with further manuscripts currently subject to peer-review.

Commentary

"Over 16,000 doses of SCENESSE® have been administered to EPP patients globally, with some patients having received continuous treatment since 2006," CLINUVEL's Chief Scientific Officer, Dr Dennis Wright said. "In this time, we have gained extensive knowledge of the product, disorder and its impact on patients' lives.

"It is apparent from analysing two decades of use, that prescribing a physiological hormone is favourable in EPP, based on the safety data which have been submitted annually to the EMA. Long-term safety is a key advantage over prospective drug candidates in development for EPP.

"CLINUVEL is seeking to harmonise the European dosage and ensure consistency in treatment options globally. Our data package supports this approach and we will continue the exchange with the European regulatory authority which may well recognise the need to provide year-round photoprotection," Dr Wright concluded.

- END -

References

- Ceresnie, M. S., et al, (2023). Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study. *Journal of the American Academy of Dermatology*, 88(4), 880–882.
- Minder, A.-E., et al, (2021). Beyond pigmentation: Signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. *Therapeutic Advances in Rare Disease*, 2, 263300402110654.
- Minder, A. (2019, August 9). On long-term afamelanotide treatment: Swiss residents with erythropoietic protoporphyria. ICPP 2019, Milan.
- Neumann, N. J. (2018). Afamelanotid. *Internistische Praxis*, 59(1), 155–159.
- O'Reilly, M., McGuire, V. A., & Dawe, R. S. (2024). Erythropoietic protoporphyria and afamelanotide: A patient's perspective. *Clinical and Experimental Dermatology*, 49(2), 186–187.
- Resnik, S. R., et al, (2023). Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. *Journal of Drugs in Dermatology: JDD*, 22(9), 941–949.
- Wensink, D., et al, (2021). Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. *Expert Review of Clinical Pharmacology*, 14(2), 151–160.

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to <https://www.clinuvel.com>.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

<https://www.clinuvel.com/investors/contact-us>

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2024 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900

Fax: +61 3 9660 4909

Email: mail@clinuvel.com

Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia

